Helen Tayton-Martin, Ph.D., M.B.A.

Helen Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol and an M.B.A. from London Business School. She has played a pivotal role in the growth and strategic direction of Adaptimmune, where she currently serves as the Chief Business & Strategy Officer. Her responsibilities include optimizing strategic and commercial opportunities for the company’s assets, leading business development, and managing alliances. Helen’s role encompasses pipeline and technology assessment, strategic portfolio analysis, and fostering partnerships with key industry players such as Astellas, Genentech, and GlaxoSmithKline. She co-founded Adaptimmune, originating from Avidex Limited, and was instrumental in the company’s transition from a small team to a robust staff of 300, culminating in a successful Nasdaq IPO. Additionally, Helen served as a non-executive director of Trillium Therapeutics Inc., contributing to its acquisition by Pfizer Inc. in November 2021.